Semaglutide GLP-1 for medical weight loss can be obtained through a prescription from a licensed healthcare provider, often at specialized weight loss clinics, endocrinology practices, or telemedicine services
Furthermore, GLP1-RA is known to be associated with decreased all-cause mortality and cardiovascular mortality in the general diabetes population 19,20,21 , but real-world data in patients with moderate to advanced kidney disease is limited
Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study
:max_bytes(150000):strip_icc()/Health-GettyImages-PharmacistsGLP1s-091528aad5314e0f94e92880dee97289.jpg)
Those who continued the medication maintained or continued to lose weight, while those who stopped regained much of the weight lost, underscoring the need for long-term therapy.23 Longer-term outcomes were assessed in STEP 5, which extended treatment to 104 weeks and demonstrated sustained weight loss of approximately 15%.24 In East Asian populations, STEP 6 showed similar results, with participants achieving an average 12% to 13% weight loss over 68 weeks.25 STEP 7, a 44-week trial including participants from China, Hong Kong, Brazil, and South Korea, found that those on semaglutide lost an average of 12.1% of their body weight compared with 3.6% with placebo.26 Lastly, STEP 8 compared semaglutide with liraglutide and showed greater efficacy with semaglutide (15.8% vs 6.4% weight loss), as well as better tolerability and more convenient weekly dosing.27 Taken together, the STEP trials show that semaglutide consistently results in clinically meaningful weight loss across various populations and treatment conditions

Biologics for cardiovascular diseases: from bench to bedside